Arthur Coli, MD
Cornea and External Diseases Specialist · Syracuse, NYNPI 1558456707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $833, 3.0 times the $276 reported in 2019.
Across 148 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$494
- Oyster Point Pharma, Inc.$459
- AbbVie$336
- Novartis$278
- Aerie Pharmaceuticals, Inc.$142
- Bausch & Lomb Americas Inc.$134
- plus $910 from 14 others
What the payments were for
- Food & beverage$2,73399%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 31 | $494 |
| Oyster Point Pharma, Inc. | 26 | $459 |
| AbbVie(2 entities) | 16 | $336 |
| Novartis | 18 | $278 |
| Aerie Pharmaceuticals, Inc. | 5 | $142 |
| Bausch & Lomb Americas Inc. | 8 | $134 |
| Kala Pharmaceuticals, Inc. | 6 | $133 |
| Amgen | 5 | $124 |
| Tarsus Pharmaceuticals, Inc. | 5 | $110 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $100 |
| Dompe US, Inc. | 5 | $87 |
| Thea Pharma Inc. | 4 | $83 |
| Sun Pharmaceutical Industries Inc. | 4 | $82 |
| Ocular Therapeutix, Inc. | 3 | $61 |
| Shire North American Group Inc | 2 | $38 |
| Biotissue Holdings Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
How this compares
$2,752 in reported general payments places this provider in the 70th percentile of 26 cornea and external diseases specialist providers in New York.
See all cornea and external diseases specialist providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 120 | $184,707 |
| LumiganBimatoprost | 162 | $100,294 |
| Cyclosporine | 35 | $31,194 |
| XiidraLifitegrast | 16 | $22,605 |
| Prednisolone Acetate | 349 | $17,937 |
| Brimonidine Tartrate | 123 | $15,547 |
| Fluorometholone | 193 | $15,240 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $11,944 |
| Alphagan PBrimonidine Tartrate | 27 | $10,636 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 49 | $9,493 |
| VyzultaLatanoprostene Bunod | 11 | $7,399 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $7,028 |
| Bimatoprost | 36 | $6,229 |
| Timolol Maleate | 176 | $5,809 |
| Latanoprost | 384 | $4,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $336 | $302,665326 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $134 | $30,00427 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $142 | $11,94413 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $100 | $2,36715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 cornea and external diseases specialist providers in New York.
Other cornea and external diseases specialist in Syracuse
- Stephen SpitzerSyracuse$2K
- Christopher StarrNew York$294K
- Joann KangBronx$14K
- Sahas NarainRockville Ctr$6K
- Jessica CiralskyNew York$6K
- Nadia HaqqieNew York$6K
- Adam ChubakPoughkeepsie$5K
- Sirikishan ShettyNew York$3K
- Alexandra HerzlichNew York$3K
- Laura PalazzoloHuntington Station$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.